Author/Editor		Černelč, Peter; Modic, Mojca
Title		Pomen novejših bioloških kazalcev za oceno prognoze pri bolnikih s kronično limfocitno levkemijo
Translated title		The importance of the new biological markers for assessing the prognosis in patients with chronic lymphocytic leukemia
Type		članek
Source		In: Križman I, editor. Interna medicina 2005: novosti in aktualnosti. Zbornik predavanj 2. kongres Združenja internistov SZD; 2005 okt 21-22; Ljubljana. Ljubljana: Slovensko zdravniško društvo, Združenje internistov,
Publication year		2005
Volume		str. 227-31
Language		slo
Abstract		Background. Chronic lymphocytic leukemia (CLL) has a variable clinical course. Well established clinical staging systems continue to form a basis for deciding when to initiate treatment and assigning prognosis in CLL. Results. Clinical staging systems usualy do not identifiy those patients with early-stage disease who will require treatment. Some new serum markers (soluble CD23), cell surface marker (CD38) and cytoplassmic proteins (ZAP-70), cytogenetics and immunoglobulin gene mutational status have all been utilised for this purpose. Conclusions. From the clinical perspective the importance of this new knowledge of biological markers is how it affects treatment.
Descriptors		LEUKEMIA, LYMPHOCYTIC, CHRONIC PROGNOSIS RECEPTORS, IGE CYTOGENETICS